Decade-long smears from @adamfeuerstein vs. $NWBO achievements as of Q3 2026:
1) CEO Linda Powers loaned company $1M
2) US DCVax-L manufacturing 100% ready
3) UK GMP ready ahead of MHRA decision
4) Dr. Kalinski’s aDC1 goes live US Q4 2026
@NorthwestBio IP @ SNO with receipts!
Have a great weekend and holiday season.
Epogen was approved to cut transfusions. Chasing the number shortened cancer patients' lives.
ALC lumps B, T and NK cells. Anktiva mainly raises NK cells, and frequent dosing exhausts them.
No survival claim has a control arm. Use a fair benchmark: pancreatic, 5.7 months versus 5.5 on routine third-line chemo. Lung, docetaxel gets 10.5 to 12 months in phase 3 trials, not the 9 it is compared with. Brain, 9.5 months on a regimen that includes bevacizumab. Bevacizumab alone got 9.2, with twice the response rate. The one randomized lung trial reported a count, not survival.
What the FDA approved is a bladder instillation, not this injection, on one 77-patient cohort with no control arm, extended last month by extrapolation. The randomized bladder trial has not been approved. Its disclosed BCG-alone figure at six months is 57%. BCG alone scored 85% in CREST and 93% in POTOMAC.
In March the FDA called his all-cancers claims false or misleading.
Japanese neocloud stock goes limit down after obliterating their revenue guidance due to losing a Chinese order over enhanced export controls.
How much of that "insane demand" has been fake this whole time?
Datasection (3905.T) just cut FY revenue guidance by 89%, from ¥162B to ¥17B, and the stock went limit-down.
This is the "Japanese neocloud" that the FT reported is effectively a Tencent datacenter: Chinese offtake, Nvidia Blackwell GPUs, Japanese flag. (1/8)🧵
You are absolutely right, MP McDonagh. Brain tumour patients cannot afford to wait. It was a pleasure speaking with you at Parliament earlier this month.
Clinical research is essential, but so is ensuring patients can access promising treatments now that have already completed major clinical trials.
DCVax-L offers real hope, and families like ours know firsthand how urgently accessible treatment options are needed.
Thank you for your continued advocacy. 💗
Regarding US manufacturing for $NWBO, the groundwork for which was recently disclosed as completed by the company in recent 10-Q, I wanted to provide my opinion on which CDMO I believe will be producing DCVax-L in the short-to-medium term for patients in the United States.
After investing heavily in the facility, including securing PILOTS in 2020 from Shelby County Tennessee, in February 2025 Charles River Labs made drastic cuts to their cell therapy business centered in the Volunteer State. This is because they acquired the facility at a market top, when capital was essentially free, while manufacturing cell therapies has significant problems reaching economies of scale thus acceptable margins for investors.
In May 2026 private equity acquired the legacy Cognate facility in Memphis from Charles River Labs and spun them out as a standalone company as Rose. This came after Elliott Investment Management (the same group that ruined Southwest Airlines) took 2025 activist position in Charles River Labs and ultimately forced this divestiture.
Though Charles River Labs may have overpaid for the facility then front-ran significant CapEx and OpEx for it before demand showed up, that doesn't mean it's any less strategic for cell therapy manufacturing in the United States.
Linda Powers built Cognate in Memphis because it's in the middle of the country and right next to the FedEx global SuperHub. This is the ideal location to manufacture and ship frozen DCVax-L to hospitals and outpatient facilities nationwide. It's already FDA, EMA, and MHRA certified with Class C (ISO 7) clean rooms in place. They also already know how to manufacture DCVax-L as this was where it was produced during the global Phase III trial.
In my opinon there's zero reason to throw away these synergies unless something significant changed with the new ownership that has not been disclosed.
I believe these Change in Control matters partially explain why it took so long to secure US manufacturing.
Though, unlike executives at Charles River Labs, Linda Powers also wisely choose to not front-run those expenses until demand required the investment.
It's a very exciting time to be a @NorthwestBio shareholder.
sec.gov/ix?doc=/Archives/edg…fiercebiotech.com/cro/charle…reuters.com/sustainability/s…prnewswire.com/news-releases…rosebiosolutions.com/#storycriver.com/products-services…
$NVDA's management doesn't want us to see the off-balance sheet debt disclosures...they prefer to keep that quiet (delay 10-q) at least until the $ANT IPO happens. The 2Q numbers were bad, like -$180 billion, this quarter will be much worse.
Microsoft was hacked, again. It looks like an advanced persistent threat within that organization. Given the events of the past few days I will say this involves a nation-state actor not script kiddies using AI agents or the "rush to patch" as that isn't how change control operates in classified NSA networks or regulated financial institutions. I do not buy that a routine Friday afternoon production change accidentally triggered a multicast storm across air traffic control networks. That isn't when scheduled changes to production occur while they should have segmentation to prevent a nation-wide outage.
For reference:
SolarWinds (Russia 2020)
Volt Typhoon (China 2023-2024)
Salt Typhoon (China 2024)
Black November (TBD 2026)
Why do I reject the excuses being promulgated in the media?
If you announce an attack in real time, you immediately tip off the adversary that they have been spotted. Their entire goal is to send a message and see how we respond.
Disclosure during an active intrusion hands an adversary free battle-damage assessment. Sparking domestic panic proves how effectively gray-zone cyber disruption could destabilize the United States during a Taiwan Strait crisis.
Incident response takes weeks to isolate hardware, map the blast radius, and rip everything out of the system, so going on TV early just lets them wipe logs and burn persistence.
Vendors of course will use this as a golden opportunity to sell you more AI-driven solutions.
Seems analogous to an arsonist selling fire insurance.
#KeepCalmAndCarryOn
Officials call it "routine maintenance" because admitting "we were scrambling to rip out a live compromise in the middle of the workday" is off-limits.
Scoop: Nvidia played matchmaking between Alibaba and Alice Huang to help the Chinese tech giant find workarounds on U.S. export controls, by @JuroOsawa@QianerLiu via @theinformation$NVDA$BABA
NVIDIA delivered extraordinary earnings. Revenue up 103%. EPS up 111%. Another monster outlook.
And yet, I think investors are looking at the wrong numbers.
Gross margins are slipping. Inventory is soaring. Receivables have more than doubled. Three customers account for 36% of revenue.
Add Jensen Huang’s departure, the reported SEC investigation and unresolved governance questions, and you’ve got a very different investment proposition.
I’ve been through enough market cycles to know that spectacular earnings don’t necessarily mean spectacular returns.
The danger isn’t always that a company stops growing. It’s that investors keep paying a premium long after the risks have changed.
A great business can still be a terrible investment at the wrong price.
Buy companies, not headlines. And never confuse an earnings beat with an all-clear. $NVDA
First, publish Jensen’s numbers to reassure investors. Then, take a closer look at what’s baked into those numbers?
Why would a former $5 trillion company take weeks to file its 10-Q, as if it were a suspicious company that had just changed its auditor (e.g., SMCI)?
Muddy Waters is short $NVDA
A woman identified as Cenly Chen, referred to in some photograph tags as Cenly Puri, has been photographed in public between 2024 to 2026 with Ajay K. Puri. Until this June, Mr. Puri was likely the third most senior executive at NVDA, behind only Jensen Huang and Colette Kress. His title was EVP Worldwide Field Operations and his total compensation was slightly above Ms. Kress’ in fiscal years 2024 to 2026.4 Mr. Puri was one of only five NVDA executives named in the 2026 Proxy.
Separately, consolidated class action complaint filed against Super Micro Computer Inc. in October 2026 alleges that former SMCI Chief Growth Officer, a woman named Cenly Chen, “managed [SMCI’s] acquisition of GPU chips from NVIDIA” and “decided how to distribute [NVDA GPUs] among Super Micro’s customers.” In March this year, the U.S. indicted three individuals associated with SMCI, including a co-founder, for illegally selling at least approximately $2.5 billion of SMCI servers with NVDA GPUs to end customers in China through a Southeast Asian front company. Referring to the ex-SMCI executive, the class action complaint alleges that there was “no way Cenly Chen lacked knowledge of [SMCI’s] illicit sales.”
Mr. Puri left NVDA in late June 2026, and the former SMCI executive named Cenly Chen left SMCI in late April or early May 2026. Mr. Puri continues to serve in a senior advisory role to NVDA.
Nobody by the name of Cenly Chen has been indicted or otherwise accused of criminal conduct by any government. The allegations in the class action are unproven.
The question is whether the woman identified as Cenly Chen or Cenly Puri in photographs with Mr. Puri is the same Cenly Chen formerly employed by SMCI.